Logo image of BIOR

BIORA THERAPEUTICS INC (BIOR) Stock Fundamental Analysis

NASDAQ:BIOR - Nasdaq - US74319F3055 - Common Stock - Currency: USD

0.5597  -0.79 (-58.54%)

After market: 0.579 +0.02 (+3.45%)

Fundamental Rating

2

Taking everything into account, BIOR scores 2 out of 10 in our fundamental rating. BIOR was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of BIOR have multiple concerns. While showing a medium growth rate, BIOR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BIOR has reported negative net income.
In the past year BIOR has reported a negative cash flow from operations.
BIOR had negative earnings in each of the past 5 years.
In the past 5 years BIOR always reported negative operating cash flow.
BIOR Yearly Net Income VS EBIT VS OCF VS FCFBIOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

With a Return On Assets value of -217.44%, BIOR is not doing good in the industry: 91.15% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -217.44%
ROE N/A
ROIC N/A
ROA(3y)-232.13%
ROA(5y)-209.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIOR Yearly ROA, ROE, ROICBIOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BIOR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIOR Yearly Profit, Operating, Gross MarginsBIOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -1M -2M -3M

More info and screens

1

2. Health

2.1 Basic Checks

BIOR does not have a ROIC to compare to the WACC, probably because it is not profitable.
BIOR has less shares outstanding than it did 1 year ago.
The number of shares outstanding for BIOR has been increased compared to 5 years ago.
The debt/assets ratio for BIOR has been reduced compared to a year ago.
BIOR Yearly Shares OutstandingBIOR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
BIOR Yearly Total Debt VS Total AssetsBIOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

BIOR has an Altman-Z score of -116.59. This is a bad value and indicates that BIOR is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -116.59, BIOR is not doing good in the industry: 98.05% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -116.59
ROIC/WACCN/A
WACC2.47%
BIOR Yearly LT Debt VS Equity VS FCFBIOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M

2.3 Liquidity

BIOR has a Current Ratio of 0.05. This is a bad value and indicates that BIOR is not financially healthy enough and could expect problems in meeting its short term obligations.
BIOR's Current ratio of 0.05 is on the low side compared to the rest of the industry. BIOR is outperformed by 99.29% of its industry peers.
A Quick Ratio of 0.05 indicates that BIOR may have some problems paying its short term obligations.
The Quick ratio of BIOR (0.05) is worse than 99.29% of its industry peers.
Industry RankSector Rank
Current Ratio 0.05
Quick Ratio 0.05
BIOR Yearly Current Assets VS Current LiabilitesBIOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

BIOR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -22.72%.
BIOR shows a strong growth in Revenue. In the last year, the Revenue has grown by 8820.00%.
Measured over the past years, BIOR shows a very negative growth in Revenue. The Revenue has been decreasing by -87.44% on average per year.
EPS 1Y (TTM)-22.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.69%
Revenue 1Y (TTM)8820%
Revenue growth 3Y-72.86%
Revenue growth 5Y-87.44%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BIOR will show a very strong growth in Earnings Per Share. The EPS will grow by 24.30% on average per year.
The Revenue is expected to grow by 933.87% on average over the next years. This is a very strong growth
EPS Next Y88.79%
EPS Next 2Y38.19%
EPS Next 3Y24.3%
EPS Next 5YN/A
Revenue Next Year39100%
Revenue Next 2Y3064.14%
Revenue Next 3Y933.87%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BIOR Yearly Revenue VS EstimatesBIOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M
BIOR Yearly EPS VS EstimatesBIOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -500 -1K -1.5K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BIOR. In the last year negative earnings were reported.
Also next year BIOR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIOR Price Earnings VS Forward Price EarningsBIOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIOR Per share dataBIOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

A more expensive valuation may be justified as BIOR's earnings are expected to grow with 24.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.19%
EPS Next 3Y24.3%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BIOR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIORA THERAPEUTICS INC

NASDAQ:BIOR (12/10/2024, 8:09:45 PM)

After market: 0.579 +0.02 (+3.45%)

0.5597

-0.79 (-58.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)N/A N/A
Inst Owners38.19%
Inst Owner Change-10.29%
Ins Owners0.61%
Ins Owner Change0%
Market Cap2.53M
Analysts82.86
Price Target34.68 (6096.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)55.44%
Min EPS beat(2)-28.34%
Max EPS beat(2)139.22%
EPS beat(4)2
Avg EPS beat(4)44.55%
Min EPS beat(4)-28.34%
Max EPS beat(4)139.22%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)248.72%
EPS NQ rev (1m)10.81%
EPS NQ rev (3m)-695.18%
EPS NY rev (1m)-2.43%
EPS NY rev (3m)-924.29%
Revenue NQ rev (1m)-54.55%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-23.46%
Revenue NY rev (3m)-23.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.84
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-10.84
EYN/A
EPS(NY)-7.46
Fwd EYN/A
FCF(TTM)-10.22
FCFYN/A
OCF(TTM)-10.16
OCFYN/A
SpS0.2
BVpS-23.59
TBVpS-24.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -217.44%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-232.13%
ROA(5y)-209.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 62.81%
Cap/Sales 31.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.05
Quick Ratio 0.05
Altman-Z -116.59
F-Score4
WACC2.47%
ROIC/WACCN/A
Cap/Depr(3y)55.03%
Cap/Depr(5y)64.29%
Cap/Sales(3y)970%
Cap/Sales(5y)1076.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.69%
EPS Next Y88.79%
EPS Next 2Y38.19%
EPS Next 3Y24.3%
EPS Next 5YN/A
Revenue 1Y (TTM)8820%
Revenue growth 3Y-72.86%
Revenue growth 5Y-87.44%
Sales Q2Q%N/A
Revenue Next Year39100%
Revenue Next 2Y3064.14%
Revenue Next 3Y933.87%
Revenue Next 5YN/A
EBIT growth 1Y9.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.32%
EBIT Next 3Y-5.74%
EBIT Next 5YN/A
FCF growth 1Y50.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.85%
OCF growth 3YN/A
OCF growth 5YN/A